AMSBIO: Scalable Protocol to Differentiate Skeletal Muscle Cells from Stem Cells

AMSBIO announces the availability of the world's first kit to differentiate human pluripotent stem cells into functional myotubes. The new kit utilizes a highly efficient media based protocol to produce skeletal muscle cells from stem cells in a simple, scalable manner.

The potential to differentiate stem cells into specific cell types is revolutionizing life sciences, from new methods of studying developmental biology and novel approaches to producing accurate disease models to techniques to help drug discovery and toxicity testing.

 

 

Until recently methods of studying muscular disease and potential therapies were dependent on invasive muscle biopsies to produce limited batches of primary cells. Use of primary cells presents challenges, not only in the collection process but also related to inconsistencies in cell growth, behavior and life span, making it difficult to generate reliable experimental models. 

 

The new Skeletal Muscle Differentiation kit offers researchers a unique tool to rapidly differentiate donor stems into functional myotubes in a reproducible fashion. Tested on a wide range of human embryonic and induced pluripotent stem cell lines the new kit follows a simple 3-step process of media changes and cell passaging. Eliminating the need for cell sorting or transfection of myogenic transcription factors, the three step protocol generates a highly pure population of approximately 70 per cent skeletal muscle myotubes in weeks.

For further information on the Skeletal Muscle Differentiation kit please visit www.amsbio.com/skeletal-muscle-differentiation-kits.aspx or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.

---------------------

Worldwide HQ 

AMS Biotechnology (AMSBIO)

184 Milton Park
Abingdon

Oxon OX14 4SE

UK

Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com 
Web www.amsbio.com

 

 

North American HQ

 

AMSBIO LLC
1035 Cambridge Street
Cambridge
MA 02141
USA

Tel:      +1.617.945.5033 
Tel:      +1.800.987.0985 (toll free)
Email: info@amsbio.com 
Web www.amsbio.com